Regenacy Pharmaceuticals is developing a novel, disease-modifying approach to treating peripheral neuropathies that goes beyond pain and symptom management to restore peripheral nerve function. Their lead compound ricolinostat (ACY-1215) is an oral, selective inhibitor of the microtubule modifying enzyme HDAC6 with first-in-class potential, that will be entering a proof-of-concept (PoC) Phase 2 clinical trial in diabetic peripheral neuropathy. Their investigation of ricolinostat for diabetic, chemotherapy-induced, and inherited peripheral neuropathies is based on compelling PoC preclinical studies demonstrating restoration of normal nerve function.